Summit Therapeutics Inc. (SMMT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Summit Therapeutics reported revenue of $0. Net income was -$1.08B, or -$1.44 per diluted share. Operating activities generated -$322.9M of cash, leaving -$323.6M of free cash flow. At fiscal year end, Summit Therapeutics held $751.2M in total assets against $92.3M in total liabilities, including $225.3M of cash and equivalents.
Open the full interactive Summit Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Summit Therapeutics Key Stats
| Share Price | $15.52 |
|---|---|
| Market Cap | $12.08B |
| 52-Week Range | $12.43 – $26.38 |
| Shares Outstanding | 778.2 million (basic, 2026 Q2) |
Summit Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $860,000 | $1.8M | $705,000 | $0 | $0 | $0 |
| Operating Income | -$53.2M | -$86.2M | -$72.1M | -$609.6M | -$226.0M | — |
| Pre-Tax Income | -$52.9M | -$88.6M | -$78.8M | -$614.9M | -$221.3M | -$1.08B |
| Income Tax | -$213,000 | $0 | — | — | — | $0 |
| Net Income | -$52.7M | -$88.6M | -$78.8M | -$614.9M | -$221.3M | -$1.08B |
| Diluted EPS | -$0.76 | -$0.96 | -$0.41 | -$0.99 | -$0.31 | -$1.44 |
Summit Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$231.8M | -$219.2M | -$189.4M | -$215.7M |
| Diluted EPS | -$0.31 | -$0.29 | -$0.24 | -$0.28 |
Summit Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $66.4M | — | $348.6M | $71.4M | $104.9M | $225.3M |
| Current Assets | $87.7M | $97.3M | $656.7M | $189.7M | $423.8M | $720.3M |
| Total Assets | $102.5M | $113.4M | $664.2M | $202.9M | $435.6M | $751.2M |
| Current Liabilities | $19.9M | $25.6M | $38.8M | $20.4M | $41.7M | $73.0M |
| Total Long-Term Debt | — | — | — | $100.0M | — | — |
| Total Liabilities | $23.0M | $30.1M | $537.5M | $125.3M | $46.8M | $92.3M |
| Shareholders' Equity | $79.5M | $83.3M | $126.7M | $77.7M | $388.7M | $658.9M |
Summit Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$48.1M | -$72.6M | -$41.6M | -$76.8M | -$142.1M | -$322.9M |
| Cash From Investing | -$421,000 | -$306,000 | -$624,000 | -$587.8M | -$205.3M | -$174.3M |
| Cash From Financing | $50.6M | $77.9M | $620.2M | $86.5M | $381.2M | $617.5M |
| Free Cash Flow | -$48.5M | -$72.9M | -$42.2M | -$76.9M | -$142.2M | -$323.6M |
| Dividends Paid | $0 | — | — | — | — | — |
Figures from Summit Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Summit Therapeutics financials page for every line item.
Summit Therapeutics Company Profile
| Ticker | SMMT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Miami, Florida |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001599298 |
Frequently Asked Questions
What was Summit Therapeutics' revenue in fiscal 2025?
Summit Therapeutics (SMMT) reported revenue of $0 for fiscal 2025.
What is Summit Therapeutics' annual revenue history?
Summit Therapeutics' annual revenue by fiscal year: 2020: $860,000; 2021: $1.8M; 2022: $705,000; 2023: $0; 2024: $0; 2025: $0.
What was Summit Therapeutics' net income in fiscal 2025?
Summit Therapeutics reported net income of -$1.08B for fiscal 2025.
What was Summit Therapeutics' earnings per share (EPS) in fiscal 2025?
Summit Therapeutics' diluted EPS was -$1.44 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Summit Therapeutics generate in fiscal 2025?
Summit Therapeutics generated -$323.6M of free cash flow in fiscal 2025.
What was Summit Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Summit Therapeutics reported revenue of $0.
How many shares of Summit Therapeutics are outstanding?
Summit Therapeutics reported a weighted average of 778.2 million basic shares outstanding in 2026 Q2.
What is Summit Therapeutics' market cap?
Based on its latest closing price, Summit Therapeutics (SMMT) has a market capitalization of about $12.08B.
When does Summit Therapeutics' fiscal year end?
Summit Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Summit Therapeutics headquartered?
Summit Therapeutics lists its business address in Miami, Florida in its SEC filings.